The adhesion of platelets to collagen and their activation is the primary event in haemostasis. Following adhesion, platelet aggregation mediated by ADP, thromboxane A2 and thrombin leads to the formation of a platelet plug. It is known that platelet activation by each of these agonists involves an increase in the cytosolic free Ca2+ concentration, and this has been thought to be controlled by cyclic AMP. However, we report here that while signal transduction induced by ADP plus a thromboxane mimetic (U46619), or by thrombin, is inhibited by stimulators of adenylate cyclase such as a prostaglandin 12 (PGI2) analogue (Iloprost), PGD2 and forskolin, elevation of cyclic AMP does not inhibit either platelet adhesion to collagen or the associated Ca2+ mobilization, phosphatidic acid formation or 5-hydroxytryptamine secretion. Furthermore, collagen did not lower elevated levels of cyclic AMP in platelets measured in the presence of both a thromboxane antagonist and an ADP-removing system. The present results are discussed in the context of previous findings.
INTRODUCTION
Many investigators have studied the effects of agents that elevate cyclic AMP on platelet adhesion to collagen and have come to varying conclusions. For example, Higgs et al. [1] and Weiss & Turrito [2] studied the effect of prostaglandin I2 (PGI2) on the adhesion of platelets to rabbit aortic subendothelium, and concluded that it prevented the formation of thrombi at very low concentrations and partially inhibited platelet adhesion at high concentrations. Cazenave et al. [3] studied platelet adhesion in the presence of apyrase to remove released ADP, and found that PGI2 inhibited the attachment of 51Cr-labelled platelets to a collagen-coated glass rod by up to 45 %. Karniguan et al. [4] concluded that PGI2 almost completely inhibited the adhesion of platelets to suspended collagen fibrils. On the other hand, in subsequent studies both Shadle & Barondes [5] and Santoro [6] concluded that PGE1 had no effect on platelet adhesion to collagen immobilized on plastic or polystyrene dishes. More recently, based on their own results and analysis of the literature, Mazurov et al. [7] concluded that agents that increase cyclic AMP have no effect on the initial attachment of platelets to collagen, but do affect subsequent responses such as spreading and aggregation.
Cyclic AMP is thought to prevent nearly all aspects of platelet activation. Another second messenger, Ca2 , on the other hand, is thought to be an important signal involved in the agonistinduced activation of platelets to aggregate, secrete and generate thromboxane A2. Stimulation of platelets with ADP, the thromboxane mimetic U46619 or thrombin results in a rapid increase in the cytosolic free Ca2+ concentration ([Ca2+]1) [8, 9] . [9, 10] . We have recently developed a novel suspension assay to study the adhesion of platelets to collagen in the presence of antagonists of secondary mediators [11] , and have determined by use of this assay that facile adhesion requires metabolic energy and actin polymerization, and evokes an increase in [Ca2l] , [12] . Therefore we decided to re-investigate the effect of cyclic AMP on the collagen-platelet interaction. We report here the unexpected finding that elevation of cyclic AMP does not inhibit collageninduced signal transduction.
EXPERIMENTAL
Human blood was obtained from healthy volunteers who denied taking any drug during the previous week. The blood was anticoagulated with citric acid/citrate/dextrose [13] and centrifuged at 180 g for 15 min at room temperature to obtain plateletrich plasma. The platelet-rich plasma was centrifuged at 800 g for 20 min at room temperature to obtain a platelet pellet. For adhesion measurements, the pellet was resuspended in 5 ml of autologous plasma and incubated for 1 h with [9,10-3H(n)]oleic acid (5 uCi/ml; 8.9 Ci/mmol) at 37 'C. In most experiments, fura-2 acetoxymethyl ester (3 tM) also was included. Following incubation, the platelets were separated from unincorporated radiolabel by gel filtration on a Sepharose 2B column using a Ca2+-free Tyrode's buffer supplemented with 0.2% fatty acidfree BSA [14] . The platelets were adjusted to 2 x 108 cells/ml. Samples of 1 ml were stirred at 800 rev./min at 37 'C for 1 min before the addition of feedback inhibitors and collagen as described elsewhere [12] . Adhesion was determined after vacuum filtration through a 10 ,um nylon mesh. Blanks, included to control for non-specific trapping of the platelets on the mesh, gave results of between 1 and 3 % of the radioactivity passed through the filter. Addition of 50 ,tg of collagen/ml to platelet suspensions altered the pH by less than 0.1 unit.
Fura-2 fluorescence was monitored continuously using settings of 340 nm (excitation) and 510 nm (emission). Fura-2 signals were calibrated as described elsewhere [15] (Fig. 1 b) , PGD2 (c) and forskolin (d). The adhesion of the pretreated platelets to collagen was significantly greater than for the control (P < 0.01), with mean values for adhesion ranging between 43.3 and 45.7 %.
In addition, the rate of increase in [Ca2+]i in the treated cells was 2.5-fold greater than in the control cells (P < 0.01), the maximal level was of a slightly greater magnitude, and the Ca2+ transient declined 3.5-fold more rapidly (P < 0.01).
Fig 
DISCUSSION
We have previously suggested that experiments studying the interaction of platelets with collagen should concurrently measure adhesion and stimulus-response coupling, should distinguish the primary response to the agonist collagen from the secondary response induced by released ADP and thromboxane A2, and should be conducted at a sufficiently high concentration of collagen to elicit signal transduction in a significant number of platelets [12] . For at 100 ,ug of collagen/ml where 60 % of the platelets adhere [11] . In the present studies, we show that the response to the primary agonist collagen is not inhibited by elevating the cyclic AMP level and, in fact, is somewhat accelerated.
In 1979, Haslam and co-workers [18] induced by thrombin even w-hen it was -studied in the presence of inhibitors of feedback pathways (Fig. 2) . Interestingly, the elevation of [Ca2+]i by thrombin was somewhat less than that reported previously [8] , reflecting inhibition of the autocrine stimulation by ADP and thromboxane A2. Mazurov et al. [7] observed that some collagen preparations lowered elevated levels of cyclic AMP in platelets, while others did not. The ability to lower cyclic AMP seemed to correlate with the efficacy with which the collagen induced platelet aggregation and secretion. These experiments were performed in the presence of both indomethacin and phosphocreatine/creatine kinase. However, the decrease in cyclic AMP was minor and it was not demonstrated that the ability of ADP to lower cyclic AMP [20] was overcome by their phosphocreatine/creatine kinase combination. We (Fig. 3) . It is known that after thrombin stimulation the majority of this PtdOH contains stearic and arachidonic acids, indicating that it is formed by phosphorylation of diacylglycerol produced in the phospholipase C pathway [22] . Of course, it is possible that PtdOH formed in response to collagen may originate directly by a phospholipase D-type reaction. Furthermore, it is possible that different receptors are coupled to different phospholipase C isoenzymes, only some of which are substrates for cyclic AMPdependent protein kinase. Alternate hypotheses [23] that may explain the ability ofcyclic AMP-dependent reactions to suppress increases in [Ca2+]i induced by thrombin, ADP and U46619, but not those induced by collagen, relate to receptors or guaninenucleotide-regulatory proteins. In this regard, Lerea et al. [24] have shown that elevation of cyclic AMP decreases the number of high-affinity binding sites for thrombin, suggesting that the thrombin receptor may be down-regulated by phosphorylation mediated by protein kinase A. A possible reason for the discriminatory effects of cyclic AMP could be that the collagen receptor is thought to be a heterodimeric integrin [25] , while those for thrombin [24] and thromboxane A2 [26] possess seven putative transmembrane domains.
